Haverford Trust Co Sells 12,901 Shares of Pfizer Inc. (NYSE:PFE)

Haverford Trust Co reduced its stake in Pfizer Inc. (NYSE:PFE) by 2.6% during the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 492,217 shares of the biopharmaceutical company’s stock after selling 12,901 shares during the quarter. Haverford Trust Co’s holdings in Pfizer were worth $14,245,000 at the end of the most recent quarter.

A number of other institutional investors also recently bought and sold shares of the stock. Olistico Wealth LLC bought a new position in shares of Pfizer in the 2nd quarter valued at about $25,000. MFA Wealth Advisors LLC bought a new stake in Pfizer in the second quarter worth about $29,000. Quarry LP bought a new stake in Pfizer in the second quarter worth about $31,000. Financial Connections Group Inc. bought a new stake in Pfizer in the second quarter worth about $34,000. Finally, ESL Trust Services LLC purchased a new position in Pfizer during the 1st quarter valued at $37,000. 68.36% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other Pfizer news, Director Scott Gottlieb bought 1,000 shares of the business’s stock in a transaction on Wednesday, October 30th. The stock was bought at an average price of $28.24 per share, with a total value of $28,240.00. Following the completion of the purchase, the director now directly owns 10,000 shares in the company, valued at $282,400. The trade was a 0.00 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 0.06% of the stock is owned by insiders.

Analyst Ratings Changes

PFE has been the subject of a number of recent analyst reports. Cantor Fitzgerald restated an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Daiwa America upgraded Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Sanford C. Bernstein began coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 target price for the company. Wells Fargo & Company upped their target price on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Finally, Barclays upped their target price on Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, five have assigned a buy rating and three have given a strong buy rating to the stock. According to MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and an average price target of $33.58.

Pfizer Stock Performance

NYSE PFE opened at $26.18 on Wednesday. The company has a market cap of $148.36 billion, a PE ratio of 35.38, a price-to-earnings-growth ratio of 0.83 and a beta of 0.67. The stock’s 50 day simple moving average is $28.84 and its 200-day simple moving average is $28.67. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, beating the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The firm had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter last year, the firm earned ($0.17) earnings per share. The business’s revenue for the quarter was up 31.2% on a year-over-year basis. As a group, equities research analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date of this dividend is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.42%. Pfizer’s dividend payout ratio (DPR) is 227.03%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.